Delving into the Latest Updates on Ferrous Succinate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ferrous succinate

Target-

Mechanism

Fe modulators

Therapeutic Areas

Endocrinology and Metabolic DiseaseHemic and Lymphatic DiseasesNervous System Diseases+ [2]

Active Indication

Anemia, Iron-DeficiencyCognitive DysfunctionIschemic Attack, Transient+ [1]

Inactive Indication-

Originator Organization-

Active Organization

Capital Medical University

Beijing Tiantan Biological Products Corp. Ltd.Nanjing Jinling Pharmacy Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC4H6FeO4

InChIKeyVAMMNAAZSNNEDJ-UHFFFAOYSA-N

CAS Registry10030-90-7

Iron deficiency is prevalent worldwide, and iron supplementation is a promising strategy to address iron needs of the body. However, traditional oral supplements such as ferrous sulfate, ferrous succinate, and ferrous gluconate are absorbed in the form of ferrous ions, leading to lipid peroxidation and side effects due to other reasons. In recent years, saccharide-iron (III) complexes (SICs) as novel iron supplements have aroused attention for the high iron absorption rate and no gastrointestinal irritation at oral doses. In addition, research on the biological activities of SICs revealed that they also exhibited good abilities in treating anemia, eliminating free radicals, and regulating the immune response. This review focused on the preparation, structural characterization, and bioactivities of these new iron supplements, as promising candidates for the prevention and treatment of iron deficiency.

01 Oct 2024·Journal of Family Medicine and Primary Care

Comparison of the effectiveness of ferrous ascorbate with ferrous sulphate in improving haemoglobin percentage among ante-natal mothers in rural field practice area of a medical college

Article

Author: Vadlamani, Sarada ; Kandipudi, Kesava Lakshmi Prasad ; Govindaraju, S L Manojna ; Yalamanchili, Padmasri

ABSTRACT:

Background::

Anaemia in pregnancy is defined by the World Health Organisation (WHO) as a haemoglobin concentration of less than 11 g/dl in venous blood. The prevalence of anaemia among ante-natal mothers in India is 50.3%[3]. The government of India supplies ferrous sulphate for prophylaxis and treatment of anaemia among ante-natal mothers for free through the reproductive maternal neonatal and child health + adolescent (RMNCH+A) programme. However, patient compliance is poor due to gastrointestinal disturbances (of all registered pregnancies, less than 1/3 consumed a full course of ferrous sulphate). Previous studies in different settings have shown increased compliance and higher mean haemoglobin levels with ferrous ascorbate, which is more affordable than other commercially available compounds.

Objective::

Hence, the current study was done to compare the effectiveness of ferrous ascorbate with ferrous sulphate in improving haemoglobin percentage among ante-natal mothers in a rural field practice area of a medical college.

Methods::

An interventional community-based study was conducted in the rural field practice area of Andhra Medical College. The study was done among 76 registered (registered at Rural Primary Health Centre Simhachalam) ante-natal mothers in gestational age 13–17 weeks with haemoglobin concentration of 7–10.9 g/dl (mild to moderate anaemia) after taking informed consent. The study was performed for two years. Ante-natal mothers who were registered but unavailable during the study period, with a medical history of haematological disorders, chronic cardiac and kidney diseases, known or suspected to have sensitivity to iron compounds, with known thyroid dysfunction or mental illness were excluded from the study.

Results::

There was a rise in haemoglobin among the entire study population, which was statistically significant (P < 0.0001). There was a higher rise in haemoglobin among the antenatal women who took ferrous ascorbate than among those who took ferrous sulphate (mean difference = 0.344 gm/dl) after 12 weeks of follow-up, which was statistically significant (P = 0.014).

Conclusion::

The study compared the effectiveness of ferrous ascorbate with ferrous sulphate in improving haemoglobin percentage among antenatal mothers in a medical college’s rural field practice area. There was a significant rise in haemoglobin percentage among the study group, which was on ferrous ascorbate with better compliance and fewer gastrointestinal side effects.

01 Jul 2024·Indian pediatrics

Comparative Efficacy of Ferrous, Ferric and Liposomal Iron Preparations for Prophylaxis in Infants

Article

Author: Konuksever, Dilek ; Özbek, Namik Yasar ; Kiliç, Betül Orhan

OBJECTIVE:

This study aimed to assess the efficacy of different oral iron preparations prescribed for prevention of iron deficiency anemia in healthy infants.

METHODS:

This retrospective study enrolled infants aged between 6 and 12 months who were initiated on iron prophylaxis at four months of age. Enrolled children consistently used specific iron preparations (ferrous, ferric or liposomal iron) and had their complete blood counts and serum ferritin levels assessed within the 6-12 month timeframe. Blood values and iron prophylaxis type (ferrous (Fe+2), ferric (Fe+3), liposomal iron) were recorded. Chi-square test was used to compare the hemoglobin and ferritin levels levels between groups. Univariate and multivariate regression analyses assessed the risk of anemia.

RESULTS:

The study included 371 children (ferrous sulphate - 60, iron hydroxide-polymaltose complex - 137 and liposomal ferric pyrophosphate - 174) with a mean (SD) age 9.1 (1.3) mo. Iron deficiency in different groups were: liposomal iron (46.0%), ferric iron (44.5%), and ferrous iron (5.0%). Mean (SD) serum ferritin levels (µg/L) were higher in the ferrous group [30.1 (10.8)] compared to infants receiving ferric [17.6 (14.50)] and liposomal iron [15.4 (12.1)] (P < 0.001). Mean (SD) hemoglobin levels (g/dL) were significantly higher in the ferrous group [12.4 (0.8)] compared to ferric [11.9 (1.1)] and liposomal iron group [12.0 (1.1)]; P =0.008. Multiple regression analysis showed that ferrous group was associated with a lower risk of iron deficiency [OR (95% CI) 0.04 (0.01-0.15), P < 0.001].

CONCLUSION:

Ferrous iron demonstrated superior efficacy compared to ferric and liposomal iron. Further studies are needed to establish alternative iron preprations in children.

100 Deals associated with Ferrous Succinate

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anemia, Iron-Deficiency	CN	Nanjing Jinling Pharmacy Co., Ltd.	01 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 2	CN	Capital Medical University	24 May 2024
Cognitive Dysfunction	Phase 2	-	Beijing Tiantan Biological Products Corp. Ltd.	24 May 2024
Ischemic Attack, Transient	Phase 2	CN	Capital Medical University	24 May 2024
Ischemic Attack, Transient	Phase 2	-	Beijing Tiantan Biological Products Corp. Ltd.	24 May 2024
Stroke	Phase 2	CN	Capital Medical University	24 May 2024
Stroke	Phase 2	-	Beijing Tiantan Biological Products Corp. Ltd.	24 May 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CSCO2022	Not Applicable	Anemia \| Uterine Cervical Cancer	100	琥珀酸亚铁联合维生素C	wgunwzeppt(xdxstqvuam) = riwlgfniwr pziiiivwdq (nfgwtungab ) View more	Positive	21 Sep 2022